Primary Immune Deficiency Disorder Clinical Trial
Official title:
Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.
Clinical phase 3 study to evaluate the efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases.
Octanorm (cutaquig®) is a 16.5% human normal immunoglobulin solution developed by Octapharma for subcutaneous administration (SCIG). It is supplied as a liquid formulation ready to use. One important therapeutic use of immunoglobulins is to provide antibodies to prevent viral and bacterial diseases (replacement therapy). Children and adults with a Primary Immunodeficiency Disease (PID) have an increased risk of recurrent bacterial and viral infections. These diseases can be severe and can lead to substantial morbidity. Responses to antibacterial therapy are often poor. At present, most primary immune deficiencies are not curable, but SCIGs have been shown to decrease the total number of severe infections and the duration of hospitalization. This study evaluated the efficacy, safety and tolerability of octanorm in adult PID patients in an open-label, multi center, phase 3 study with an 8-week wash-in/wash-out period followed by a 6-month efficacy period ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03939533 -
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
|
Phase 3 | |
| Recruiting |
NCT03266640 -
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
|
Phase 2 | |
| Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
| Completed |
NCT01859754 -
Octagam 5% Versus Comparator Post Marketing Trial
|
||
| Recruiting |
NCT03148028 -
Immunological Characteristics of Patients With PID and IBD
|
N/A | |
| Active, not recruiting |
NCT04354818 -
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
|
||
| Completed |
NCT01888484 -
Study of Octanorm Subcutaneous IG in Patients With PID
|
Phase 3 | |
| Completed |
NCT01131858 -
Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency
|
Phase 1/Phase 2 | |
| Completed |
NCT03211689 -
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
|
N/A | |
| Terminated |
NCT01883921 -
Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
|
||
| Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
| Completed |
NCT02327351 -
TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
|
Phase 2/Phase 3 | |
| Completed |
NCT03618147 -
Primary Immunodeficiency in Kuwait
|
||
| Recruiting |
NCT04197596 -
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03422614 -
Pathophysiology of Inborn Immunodeficiencies
|
N/A | |
| Completed |
NCT02888535 -
Intensive Care Unit and Secondary and Primary Immune Deficiency
|
||
| Recruiting |
NCT04232085 -
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
|
Phase 2 | |
| Active, not recruiting |
NCT03037359 -
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
|
||
| Completed |
NCT03069079 -
Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study
|
N/A | |
| Recruiting |
NCT03414528 -
Identification of New Inborn Errors of Immunity
|
N/A |